Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review

INTRODUCTION: Intravenous immunoglobulin (IVIG) was reported to be the third most used monotherapy in livedoid vasculopathy (LV). There is currently a lack of randomized controlled clinical trials and no standardized therapeutic regimen for IVIG therapy in LV. METHODS: We performed a systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yimeng, Jin, Hongzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134453/
https://www.ncbi.nlm.nih.gov/pubmed/35634570
http://dx.doi.org/10.1177/20406223221097331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134453/
https://www.ncbi.nlm.nih.gov/pubmed/35634570
http://dx.doi.org/10.1177/20406223221097331

Ejemplares similares